pembrolizumab

Details

Key Milestones2
Call for patient/clinician input openFebruary 08, 2024
Call for patient/clinician input closedApril 02, 2024
Clarification:

- Patient input submission received from My Gut Feeling - Stomach Cancer Foundation of Canada

Submission receivedMarch 13, 2024
Submission acceptedMarch 28, 2024
Review initiatedApril 01, 2024
Draft CADTH review report(s) provided to sponsor for commentJune 20, 2024
Deadline for sponsors commentsJuly 02, 2024
CADTH review report(s) and responses to comments provided to sponsorAugust 01, 2024
Expert committee meeting (initial)August 14, 2024
Draft recommendation issued to sponsorAugust 27, 2024
Draft recommendation posted for stakeholder feedbackSeptember 05, 2024
End of feedback periodSeptember 19, 2024
Final recommendation issued to sponsor and drug plansOctober 04, 2024
Final recommendation postedOctober 23, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)October 21, 2024
CADTH review report(s) postedJanuary 30, 2025

ivosidenib

Details

Key Milestones2
Call for patient/clinician input openFebruary 05, 2024
Call for patient/clinician input closedApril 02, 2024
Clarification:

- Patient input submission received from The Leukemia and Lymphoma Society of Canada (LLSC) and Heal Canada

Submission receivedMarch 19, 2024
Submission acceptedApril 03, 2024
Review initiatedApril 04, 2024
Draft CADTH review report(s) provided to sponsor for commentJune 21, 2024
Deadline for sponsors commentsJuly 03, 2024
CADTH review report(s) and responses to comments provided to sponsorAugust 01, 2024
Expert committee meeting (initial)August 14, 2024
Draft recommendation issued to sponsorAugust 28, 2024
Draft recommendation posted for stakeholder feedbackSeptember 05, 2024
End of feedback periodSeptember 19, 2024
Final recommendation issued to sponsor and drug plansOctober 04, 2024
Final recommendation postedOctober 23, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)October 21, 2024
CADTH review report(s) postedJanuary 21, 2025

fidaxomicin

Details

Key Milestones2
Call for patient/clinician input open05-Feb-24
Request for Advice received29-Jan-24
Manufacturer informed of request for advice31-Jan-24
Manufacturer information or comments due14-Feb-24
Request for Advice initiated15-Feb-24
Call for patient/clinician input closed02-Apr-24
Clarification:

- Patient input submission received from the Gastrointestinal Society

Draft Canada's Drug Agency review report(s) sent to sponsor16-Apr-24
Deadline for sponsors comments25-Apr-24
Expert committee meeting (initial)26-Jun-24
Clarification:

Project was withdrawn without issuing a revised recommendation

clindamycin plus benzoyl peroxide and adapalene

Details

Key Milestones2
Call for patient/clinician input openJanuary 29, 2024
Call for patient/clinician input closedMarch 25, 2024
Clarification:

- Patient input submission received from Acne and Rosacea Society of Canada (ARSC) and Canadian Skin Patient Alliance (CSPA)

Submission receivedMarch 08, 2024
Submission acceptedMarch 26, 2024
Clarification:

- Submission was not accepted for review on 25 Mar 2024

Review initiatedMarch 27, 2024
Draft CADTH review report(s) provided to sponsor for commentJune 20, 2024
Deadline for sponsors commentsJuly 03, 2024
CADTH review report(s) and responses to comments provided to sponsorAugust 16, 2024
Expert committee meeting (initial)August 28, 2024
Draft recommendation issued to sponsorSeptember 11, 2024
Draft recommendation posted for stakeholder feedbackSeptember 19, 2024
End of feedback periodOctober 04, 2024
Final recommendation issued to sponsor and drug plansOctober 18, 2024
Final recommendation postedNovember 05, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)November 01, 2024
CADTH review report(s) postedFebruary 21, 2025

elexacaftor/tezacaftor/ivacaftor and ivacaftor

Details

Key Milestones2
Call for patient/clinician input open22-Jan-24
Call for patient/clinician input closed19-Mar-24
Clarification:

- Patient input submission received from Cystic Fibrosis Canada

Submission received05-Mar-24
Submission accepted20-Mar-24
Review initiated21-Mar-24
Draft CADTH review report(s) provided to sponsor for comment06-Jun-24
Deadline for sponsors comments17-Jun-24
CDA-AMC review report(s) and responses to comments provided to sponsor16-Aug-24
Expert committee meeting (initial)28-Aug-24
Draft recommendation issued to sponsor10-Sep-24
Draft recommendation posted for stakeholder feedback19-Sep-24
End of feedback period04-Oct-24
Final recommendation issued to sponsor and drug plans17-Oct-24
Final recommendation posted04-Nov-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)31-Oct-24
CDA-AMC review report(s) posted17-Mar-25

baricitinib

Details

Key Milestones2
Call for patient/clinician input open22-Jan-24
Call for patient/clinician input closed19-Mar-24
Clarification:

- Patient input submission received from Canadian Alopecia Areata Foundation

Submission received04-Mar-24
Submission accepted19-Mar-24
Review initiated20-Mar-24
Draft CADTH review report(s) provided to sponsor for comment07-Jun-24
Deadline for sponsors comments18-Jun-24
CADTH review report(s) and responses to comments provided to sponsor12-Jul-24
Expert committee meeting (initial)24-Jul-24
Draft recommendation issued to sponsor07-Aug-24
Draft recommendation posted for stakeholder feedback15-Aug-24
End of feedback period29-Aug-24
Final recommendation issued to sponsor and drug plans13-Sep-24
Final recommendation posted02-Oct-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)27-Sep-24
CADTH review report(s) posted07-Feb-25